The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | The CLL2-BAG trial: discovering an effective treatment for CLL
Paula Cramer, MD, from the University Hospital of Cologne, Cologne, Germany, talks to us about the CLL2-BAG trial, a Phase II study evaluating the effectiveness of a sequential treatment involving the administration of bendamustine, followed by a combination of the Bcl2 antagonist, venetoclax, and the anti-CD20 antibody, obinutuzumab, in treating patients with chronic lymphocytic leukemia (CLL). She describes in this interview that the primary endpoint, namely the overall response rate at the end of the trial, was met, a significant MRD negativity rate was observed in patients and there were no unexpected adverse effects. Thus, it appears that this treatment regimen was very efficacious and well-tolerated in CLL patients. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
